ClinicalTrials.gg
CompletedNCT03472950Updated Dec 9, 2024Results posted

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of Ranolazine 500 MG and Ranolazine 1000 MG in ALS, sponsored by University of Kansas Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University of Kansas Medical Center · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.

Read the detailed description

Amyotrophic Lateral Sclerosis (ALS) is a progressive debilitating and fatal neurodegenerative disease involving the motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord with 5,000 newly diagnosed patients per year in the USA. There is a pressing need for additional therapies, as the only two FDA-approved drugs for ALS, riluzole and edaravone, showed prolongation of median survival of only two to three months and only a modest benefit in daily functioning, respectively. The ability to identify FDA approved drugs which can be repurposed to ALS, and which may slow disease progression, alleviate symptoms, or prolong survival will have an immediate positive impact of the lives of patients with ALS and their family members. Hypothesis: Ranolazine, an FDA approved drug for angina which inhibits the late Na+ current and intracellular Ca2+ accumulation may be neuroprotective in ALS by reducing neuronal hyperexcitability, may slow disease progression and reduce cramp frequency.

02

Conditions studied

  • ALS
03

In context

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically definite, probable, laboratory supported probable, or possible ALS per revised El Escorial criteria
  • Cramp frequency greater than 4 cramps per week during 2 week run in
  • ALS functional rating scale-revised (ALSFRS-R) score of greater than 24
  • Able to lie on back for study procedures

Exclusion criteria

Exclusion Criteria:

  • Tracheostomy invasive ventilation, or use of non-invasive ventilation greater than 12 hours per day
  • Pregnant or lactating
  • Participation in a prior experimental drug trial less than 30 days prior to screening
  • Patients taking ranolazine
  • Patients taking medications which are for use with ranolazine such as strong CYP3 inhibitors (ketoconazole, clarithromycin, nelfinavir), and CYP3 inducers (rifampin, phenobarbital)
  • Patients with medical comorbidities (hepatic, renal, cardiac, etc)
  • Patients with baseline prolongation on Electrocardiography ()
  • Patients pre-disposed to secondary QT prolongation for other health conditions like family history of congenital long QT syndrome, heart failure, bradycardia, or cardiomyopathies
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Ranolazine 500mg

    Participants will take Ranolazine 500mg twice daily for up to 4 weeks.

    Drug: Ranolazine 500 MG

  • Experimental
    Ranolazine 1000mg

    Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.

    Drug: Ranolazine 1000 MG

Interventions

  • Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).

  • Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    Measured as any drug-related serious adverse event, or drug-related adverse event necessitating study withdrawal. If a dose has less than 33% DLTs it will be considered tolerable.

    Time frame: Up to Week 12

Secondary outcomes

  1. Percent Change in Cramp Frequency

    The percent change in cramp frequency: average daily cramp frequency, comparing week 12-baseline

    Time frame: Weekly for 12 weeks

  2. Percentage Change in Average Weekly Cramp Severity

    Percent change in average weekly cramp severity (1 being a very mild muscle cramp and 10 being the most severe cramp you ever experienced)

    Time frame: Weekly for 12 weeks

  3. Change in Nocturnal Awakenings Per Week, Comparing Week 12 to Baseline

    Time frame: Weekly for 12 weeks

  4. Muscle Fasciculations Count

    Time frame: Up to week 12

07

Results

Posted Dec 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneRanolazine 500mgRanolazine 1000mg
Started68
Completed64
Not completed04
Withdrew: Lost to follow-up01
Withdrew: Adverse event03

Outcome measures

PrimaryDose Limiting Toxicities (DLT)

Measured as any drug-related serious adverse event, or drug-related adverse event necessitating study withdrawal. If a dose has less than 33% DLTs it will be considered tolerable.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Dose Limiting Toxicities (DLT)
ParticipantsRanolazine 500mgRanolazine 1000mg
Dose Limiting Toxicities (DLT)12
SecondaryPercent Change in Cramp Frequency

The percent change in cramp frequency: average daily cramp frequency, comparing week 12-baseline

Time frame:
Weekly for 12 weeks
Reported as:
Mean · Percent Change in Cramp Frequency
Percent Change in Cramp Frequency
Percent Change in Cramp FrequencyRanolazine 500mgRanolazine 1000mg
Percent Change in Cramp Frequency-39.98 ± 23.94-68.38 ± 27.74
SecondaryPercentage Change in Average Weekly Cramp Severity

Percent change in average weekly cramp severity (1 being a very mild muscle cramp and 10 being the most severe cramp you ever experienced)

Time frame:
Weekly for 12 weeks
Reported as:
Mean · Percentage change in average weekly cram
Percentage Change in Average Weekly Cramp Severity
Percentage change in average weekly cramRanolazine 500mgRanolazine 1000mg
Percentage Change in Average Weekly Cramp Severity-38.68 ± 19.46-54.05 ± 39.94
SecondaryChange in Nocturnal Awakenings Per Week, Comparing Week 12 to Baseline
Time frame:
Weekly for 12 weeks
Reported as:
Mean · Number of nights awakened
Change in Nocturnal Awakenings Per Week, Comparing Week 12 to Baseline
Number of nights awakenedRanolazine 500mgRanolazine 1000mg
Change in Nocturnal Awakenings Per Week, Comparing Week 12 to Baseline-1.67 ± 2.09-4.57 ± 6.80
SecondaryMuscle Fasciculations Count
Time frame:
Up to week 12
Reported as:
Mean · Muscle fasciculations count
Muscle Fasciculations Count
Muscle fasciculations countRanolazine 500mgRanolazine 1000mg
Muscle Fasciculations Count33 ± 2558 ± 25

Adverse events

Collected over Adverse event data was collected for 12 weeks. This began at baseline visit through the week 12 visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranolazine 500mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Ranolazine 1000mg0/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRanolazine 500mgRanolazine 1000mg
ConstipationGastrointestinal disorders1/64/8
Upper respiratory infectionInfections and infestations3/61/8
Gastroesophageal refluxGastrointestinal disorders1/62/8
InfluenzaInfections and infestations0/62/8
DrowsinessGeneral disorders0/62/8
SinusitisInfections and infestations1/60/8
DizzinessEar and labyrinth disorders0/61/8
IndigestionGastrointestinal disorders0/61/8
Dental AbscessInfections and infestations0/61/8
DepressionPsychiatric disorders0/61/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ranolazine 500mgRanolazine 1000mgTotal
<=18 years000
Between 18 and 65 years5611
>=65 years123
Age, Continuous
Age, Continuous(years)Ranolazine 500mgRanolazine 1000mgTotal
Median53 (42 to 67)55 (39 to 71)54 (39 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Ranolazine 500mgRanolazine 1000mgTotal
Female123
Male5611
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ranolazine 500mgRanolazine 1000mgTotal
Caucasian6814
Non Hispanic6814
Region of Enrollment
Region of Enrollment(participants)Ranolazine 500mgRanolazine 1000mgTotal
United States6814
08

Study locations

1 site
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Dec 2020, 30 months.

Results were first posted in Dec 2024, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2018
First posted
Mar 21, 2018
StartActual
Jun 11, 2018
Primary completionActual
Dec 11, 2020
CompletionActual
Dec 9, 2022
Results first posted
Dec 9, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03472950
Collaborators
Gilead Sciences
Responsible party
Jeffrey Statland (Assistant Professor, University of Kansas Medical Center) — Principal investigator
First posted
Mar 21, 2018
Start date
Jun 11, 2018
Primary completion
Dec 11, 2020
Completion
Dec 9, 2022
Results posted
Dec 9, 2024
Last update
Dec 9, 2024

Study contacts

Jeffrey Statland, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion